Introduction
The ideal aim of any gene therapy approach for the treatment of inherited disorders should involve a lasting and tissue-specific expression of the functional gene. To this end, an in situ permanent correction of the defective endogenous gene (gene targeting approach) is obviously preferable to a transient addition of exogenous non-integrating vectors expressing the wild-type version of the gene or its cDNA (gene augmentation approach). The site-specific modification, by mechanisms of homologous recombination or gene repair, may lead to a long-term and genetically inheritable expression of the corrected gene, regardless of its size. 1, 2 Moreover, an in situ correction approach allows physiological expression, in terms of time and space of the targeted gene, since it remains under cell-specific regulatory regions. For this reason, the potential for any undesired metabolic alteration, including the host cell's silencing of the transgene, can be completely eliminated. Finally, both loss-of-function and gain-of-function mutations can be theoretically corrected by gene targeting approaches, making them versatile tools for the cure of recessive, as well as dominant disorders.
In the last 5 years, several non-viral gene targeting methods have been developed to specifically modify genomic DNA, including homologous replacement mediated by small DNA fragments (SDF), [3] [4] [5] [6] [7] [8] mediated by chimeric RNA/DNA oligonucleotides (RDO) [9] [10] [11] [12] [13] [14] or triplex-forming oligonucleotides (TFO). [15] [16] [17] [18] Relatively high correction frequencies have been reported in these studies, both in vitro and in vivo. However, with few exceptions, genomic DNA targets are generally lacking intrinsic selection mechanisms that either enrich for cells which have undergone gene correction, or directly differentiate between corrected versus parental mutant cells. As a result, gene targeting frequency can be only approximately estimated by standard RFLP-and PCR-based methods.
On the contrary, shuttle vectors carrying extrachromosomal defective and selectable genes are powerful tools to exactly quantify correction efficacy in transient transfection experiments, carried out both in vitro (nuclear extracts) and in vivo (bacterial, yeast or mammalian cells). Targeted correction of the non-functional version of these genes can be precisely and rapidly detected, as restoration of antibiotic resistance (marker genes) or phenotypical expression of novel protein products (reporter genes) in host cells. Due to their ability of conferring drug resistance to the successfully transfected cells, selectable marker genes (such as tetracycline, kanamycin or zeocin) are usually good candidates for targeting experiments. In addition, targeting of reporter genes codifying for nonendogenous and visible protein products (such as bacterial ␤-galactosidase, firefly luciferase and jellyfish green fluorescent protein) allows an accurate and fast quantification of their intracellular expression by enzymatic colorimetric, luminescent or fluorescent assays. 19 Moreover, shuttle vectors carrying both a eukaryotic antibiotic resistance gene and a defective marker gene are fundamental for the development of stable mammalian cell lines containing chromosomally integrated target genes. These cell lines can then be used in parallel and comparative chromosomal gene targeting experiments. 20 Another advantage of using episomal target genes, related to the feasibility and rapidity of the detection, is the possibility of testing and comparing several factors able to enhance or reduce targeting frequencies and to elucidate molecular mechanisms underlying each strategy. It is very likely that the success rate of each gene targeting approach varies from cell type to cell type 21, 22 and even among single experiments. 9 Furthermore, it may depend on cellular transcriptional, recombination or DNA repair activities. As a consequence, it is essential to verify the feasibility of each method in the cell line of interest, using a simpler model system. For all these reasons, after initial studies aimed at correcting chromosomal DNA sequences, several gene targeting methodologies drew back to target specific nucleotides in extrachromosomal genes (Table 1) . Although viral approaches are also now being investigated, 23 in this article we will focus on the results originated by the use of: (1) small DNA fragments (SDF); (2) chimeric RNA/DNA oligonucleotides (RDO), and (3) triplex-forming oligonucleotides (TFO).
SDF
To date, only three episomal genes have been specifically modified, using small fragments of DNA that are homologous to DNA sequence, except for the desired nucleotides to be corrected. [24] [25] [26] Previous studies have shown that extrachromosomal recombination between a firefly luciferase reporter gene and several SDF (from 290 to 2339 bp in size) was highly dependent on the length of the fragment in all the different cell lines tested (ie NIH3T3, A-549 and Jurkat cells). 24 A mismatch repair activity dependent on proteins Ku p80, ADP-rybosyl transferase, MLH1 and XP-C, was ruled out, because the correction of 2-, 4-and 7-bp deletions was observed in cells defective in those enzymes.
We used SDF (410 and 458 bp), both single-and double-stranded, to direct a site-specific deletion of 4 bp that were introduced in the extrachromosomal Zeocin antibiotic resistance (zeo r ) gene, in human airway epithelial cells. 25 In the episomal assay we developed, the most relevant parameter in increasing correction frequency was the gene delivery system utilized. A physical transfection method (ie electroporation) was 1000-fold more efficient than chemical vehicles (ie cationic liposomes and dendrimer complexes), reaching 4% of correction frequency. Furthermore, a nuclear plasmid extraction yielded 100 [26] [27] [28] Upon entering a cell, most of the fragments complexed with artificial vehicles (ie Lipofectamine or PEI) remained outside the nucleus or associated with the nuclear membrane. When the green fluorescent protein (GFP) reporter gene was used as an extrachromosomal target for gene correction, different cell types including fibroblasts, lung epithelia and hepatocytes showed significant correction of a single-point mutation with similar frequencies. 26 
RDO
Chimeric RNA/DNA oligonucleotides (RDO) have been extensively used to mediate targeted gene repair in a number of extrachromosomal genes, both in vitro and in vivo. 20, [29] [30] [31] [32] [33] The bacterial ␤-galactosidase reporter gene was used as a target in nuclear extracts from mammalian cells, in bacterial and yeast cells to: (1) compare gene correction frequencies among different cell types; 32 (2) improve the design of RDO constructs; and (3) understand the role of each strand contained in the RDO. A great variation in gene conversion frequencies among different cell types was observed in this model system. 32 A very low frequency of extrachromosomal gene targeting in human primary keratinocytes confirmed previous data showing no detectable conversion among six different chromosomal target genes in this particular cell line. 22 Conversely, DT40 cells presenting a higher homologous recombination rate showed a very high gene correction frequency, suggesting an important role for cellular recombination rate in RDO-mediated targeting. 32 Also a fundamental, albeit indirect, role of p53 protein in gene conversion was suggested.32 Very recently, the same episomal system has been used to demonstrate that short single-stranded oligonucleotides (ODN) with antisense orientation are as efficient as RDO in targeted nucleotide exchange in nuclear extracts. 20 Moreover, the construction of stable cell lines, bearing a ␤-galactosidase reporter gene integrated in their genome, allowed an accurate comparison between targeting frequencies at episomal and chromosomal levels, reaching 1% and 0.1%, respectively.
The involvement of a mismatch repair process in the gene correction of extrachromosomal genes was hypo-thesized by Kren et al 34 who observed the requirement of two mismatch repair enzymes, RecA recombinase and MutS, for RDO to mediate gene correction in a bacterial system. Further studies carried out in a mammalian cellfree system confirmed this conclusion, 30 since the addition of an antibody directed against the human MutS homolog, MSH2, led to a decrease in the gene correction frequency of two marker genes (tet r and kan r ) in cell extracts from HuH-7 hepatoma cells.
TFO
Triplex-forming oligonucleotides (TFO) are molecules that bind to a purine/pyrimidine-rich strand in the major groove of duplex DNA, producing triplex structures. 35 The delivery of TFO in several mammalian cells led to a targeted sequence alteration in an extrachromosomal supF reporter gene, with a correction frequency approaching 1%. 36 A nucleotide excision repair (NER) mechanism was argued since human mutant cell lines, defective in the NER damage recognition factor XPA, were unable to revert a single base-pair mutation, which is contrary to the same cell line expressing an exogenous XPA cDNA.
Conclusions
Extrachromosomal systems have been demonstrated to be powerful tools to determine which type of cell is amenable to targeted gene correction and to partially elucidate the mechanisms underlying each strategy. Since the frequency of RDO-mediated correction appears to vary among individual cell lines, it is likely that different cellular concentrations of repair or recombinative proteins may alter the success of this gene targeting approach.
RDO-mediated gene targeting seems to be independent of cell replication, since gene conversion by an RDO was observed in nonreplicating primary rat hepatocyte cells. 37 In addition, both RDO-and SDF-mediated correction is independent from active transcription, because gene replacement was observed in the non-transcribed ␤-globin gene of lymphoblastoid cells, HuH-7 hepatoma cells, 22 and of human airway epithelial cells. 38 Conversely, two recent studies carried out in different model systems (including nuclear extracts, mammalian and yeast cells) reported a potential role of transcription on gene repair mediated by short oligonucleotides ODN. 20, 33 In fact, an antisense ODN was 10-to 1000-times more efficient than a sense ODN in mediating both extrachromosomal and chromosomal gene targeting.
With all their limitations, due to the distinct structures of episomal versus genomic targets, extrachromosomal genes have been valuable tools in showing the effectiveness of different gene targeting strategies in a given cell line and to achieve better evaluation of targeting efficiency. Indeed, in three different cell lines (HeLa, HaCaT and primary keratinocytes) a comparable trend was demonstrated in correcting extrachromosomal or genomic targets, using the same methodology. 
